0162 Outcomes of surgery following chemoradiotherapy for anal cancer: A 10-year retrospective study
Published Date: 01st September 2019
Publication Authors: Liew S
Aim
Anal cancer accounts for less than 1% of all cancers but carries considerable morbidity and mortality. We reviewed clinicopathological outcomes for patients undergoing surgery following chemoradiotherapy (CRT) for anal cancer.
Method(s)
A retrospective review of casenotes from patients undergoing surgery for anal cancer from 2008 -2018 was performed. Patients were identified from the anal cancer MDT records and the departmental surgical logbook.
Result(s)
Forty patients were identified with a median [IQR] age of 62 [18.25] years. Out of them, 11.1% were T1, 47.2% T2, 13.8% T3 and 27.7% T4. Twenty Five patients underwent flap reconstruction of the perineum. Post-operative complications were identified in 25 patients, 7 of which were Clavien-Dindo III-IV. The overall 1, 3, and 5-year survival was 76.4%, 47.8% and 35.2% respectively. Survival was significantly lower in those with an R1 resection margin (p=0.01), but no difference was found between those having surgery for residual or recurrent disease (p=0.98).
Conclusion(s)
Chemoradiotherapy remains the gold standard for the treatment of anal cancer, with salvage surgery reserved for cases of residual or recurrent disease, or for palliation. We report a median time from completion of CRT to surgery of 12months, an R0 resection rate of 70%, and 5-year survival of 35.2%.
Leptidis, I; Sutton, P; Carter, P; Rooney, P; Liew, SH. (2019). 0162 Outcomes of surgery following chemoradiotherapy for anal cancer: A 10-year retrospective study. British Journal of Surgery. 106 (S6), 56.